Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate.
Targeted delivery of chemotherapeutic agents is a new approach for the treatment of cancer, which provides increased selectivity and decreased systemic toxicity. We have recently developed a promising drug delivery system, in which the anticancer drug daunorubicin (Dau) was attached via oxime bond t...
Main Authors: | Verena Natalie Schreier, Lilla Pethő, Erika Orbán, Andreas Marquardt, Brindusa Alina Petre, Gábor Mező, Marilena Manea |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3981732?pdf=render |
Similar Items
-
Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification
by: Sabine Schuster, et al.
Published: (2018-11-01) -
Drug targeting to decrease cardiotoxicity – determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells
by: Livia Polgár, et al.
Published: (2018-06-01) -
Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers
by: Lilla Pethő, et al.
Published: (2019-10-01) -
Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin–GnRH-III conjugates developed for targeted drug delivery
by: Sabine Schuster, et al.
Published: (2018-04-01) -
Novel Crizotinib–GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems
by: József Murányi, et al.
Published: (2019-11-01)